The Life Sciences team advised Envisagenics, Inc. on a research collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY).
The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.
Envisagenics is an artificial intelligence-driven biotechnology company that focuses on the discovery of novel RNA splicing variants that cause cancer and other genetic diseases.
For more details, read the press release.